As we near the release of findings from the Abatacept Prevention Study, two participants share how their experiences in TrialNet research helped shape their futures.

Elliot, a 17-year-old from a small village outside Bristol, recently completed treatment in the Abatacept Prevention Study. He is the first person in the United Kingdom (UK) to do so.